Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

01. Dezember 2021 16:05 ET | Quelle: Cocrystal Pharma, Inc.

Cocrystal Pharma Presents Preclinical Data from COVID-19 Antiviral Programs and Outlines Near-Term Clinical Plans at the World Antiviral Congress 2021

Unveils designs for Phase 1 and 2 studies with intranasal/pulmonary and oral SARS-CoV-2 protease inhibitors; trial initiations expected in 2022 BOTHELL, Wash., Dec. 01, 2021 (GLOBE NEWSWIRE) --...
24. August 2021 10:44 ET | Quelle: Sorrento Therapeutics, Inc.

Sorrento Therapeutics Announces Entry Into Option Agreement to Exclusively License MPRO Inhibitors Against SARS-CoV-2 and Variants of Concern, Including Delta, From Texas A&M University

MPro is a SARS-CoV-2 enzyme that catalyzes the formation of a number of essential proteins for the viral reproduction.MPro inhibitors block this catalytic process to potentially inhibit the viral...
09. Mai 2012 09:30 ET | Quelle: CellepathicRX

CellepathicRx Selected to Speak During Innovation Showcase at International CTIA Wireless(r) 2012 in New Orleans

CLEVELAND, May 9, 2012 (GLOBE NEWSWIRE) -- CellepathicRx will speak at the CTIA Executive Forum during International CTIA WIRELESS® 2012, taking place May 8-10 at the Ernest N. Morial Convention...